Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Advertising
 

EquipNet Auction: Cyteir & Moment Biosciences Late Model Lab Instruments - June 14-15

Sign Up for University of Washington Online Master of Pharmaceutical Bioengineering

Our newest cartoon revisits "Milestones in Polio"


Utah Life Science Industry Directory

World Blood Donor Day

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing UtahLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Covance


Covance
1121 East 3900 South
Building C, Suite 105
Salt Lake City, UT 84124
Covance
 
Phone: (801) 293-2400
Fax: (801) 313-6495
Year Established:  1981
Employees: 130
Ticker: LH
Exchange: NYSE
Main Contact: John Ratliff, CEO
 
Other Contacts:  Jonathan Zung, Group President, Clinical Development
Herman E. Scholtz, MD, VP & GM, Early Clinical Services
John Gransee, CFO
Jonathan Koch, Group President, R&D Laboratories
Honggang Bi, GM, China
Chris Gegelys, General Counsel
Dimitris K. Agrafiotis, PhD, FRSC, Chief Data Officer
Steven Anderson, CSO
 
Company Description

Covance is one of the world's largest and most comprehensive drug development services companies with 37 sites in 17 countries and approximately 7,000 employees.

Covance offers development services such as safety assessment, clinical pharmacology, consulting, to late-stage development services that include clinical trial management, central laboratory testing, central diagnostics, and commercializationt.

On Feb. 19, 2015, LabCorp® announced the completion of its acquisition of Covance. At closing, the purchase consideration was valued at $107.19 per Covance share, consisting of $75.76 in cash and 0.2686 LabCorp shares for each Covance share, or an equity value of $6.2 billion and an enterprise value of $5.7 billion.



Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

UtahLifeScience.com is owned and published by Info.Resource, Inc.